Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial.
J Clin Hypertens (Greenwich)
; 23(4): 870-878, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33481341
ABSTRACT
Although continuous erythropoietin receptor activators (CERAs) are widely used erythropoiesis-stimulating agents for correcting renal anemia in patients undergoing hemodialysis (HD), few reports have examined weekly CERA administration. In this randomized controlled trial, we compared the efficacy and changes in the parameters of iron metabolism and erythropoiesis between weekly and biweekly CERA administration. In total, 120 patients undergoing maintenance HD were randomized to the weekly or biweekly group. The primary end point was the total CERA dose needed to maintain the target hemoglobin (Hb) levels during a 12-week evaluation period. There was no significant difference in the total dose between the weekly and biweekly groups (median 175.0 [interquartile range (IQR) 93.8-337.5] µg/12 weeks vs. 300.0 [IQR 125.0-375.0] µg/12 weeks, P = .18). The mean Hb levels during the evaluation period were 10.9 ± 0.8 g/dL in the weekly group and 10.7 ± 0.8 g/dL in the biweekly group (P = .25). Weekly CERA administration was well tolerated. Weekly CERA administration similarly managed anemia as biweekly administration in patients undergoing HD.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematinics
/
Hypertension
/
Anemia
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Clin Hypertens (Greenwich)
Journal subject:
ANGIOLOGIA
Year:
2021
Document type:
Article
Affiliation country:
Japón